Pharma BD Deal Intelligence
Halozyme Therapeutics, Inc. (Nasdaq: HALO) disclosed on 28 January 2026, alongside its raised 2026 and multi-year financial guidance, the acquisition of privately held Surf Bio, Inc. for up to US$400 million -- US$300 million in cash upfront plus up to US$100 million in contingent milestone payments. Surf Bio's hyperconcentration technology uses excipients to formulate monoclonal antibodies and small molecules at concentrations up to approximately 500 mg/mL, three to four times typical formulations, which shrinks injection volume enough to permit single-shot subcutaneous delivery via autoinjector at home or in the physician's office. The deal gives Halozyme a third subcutaneous-delivery platform alongside ENHANZE and its high-concentration auto-injector franchise, diversifying the company beyond ENHANZE royalty concentration risk. NOTE: ingested at pending_review by bd-enrichment-2026-07-26 pending pipeline-asset and scoring enrichment.
← Browse all deals · How we score deals
More: 2026 deals